MEDIVATION, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 45 rows in 2014. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2014-12-19: Reporting owner Seely Lynn; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-12-19: Reporting owner Seely Lynn; Form 4; Security Stock Option (RIght to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2014-12-15: Reporting owner Lobacki Joseph M; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-10-22: Reporting owner Seely Lynn; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2014-12-19 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,686 89,314 owned after | $10.59 exercise price | 2014-12-22 | |
| 2014-12-19 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (RIght to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,654 0 owned after | $9.39 exercise price | 2014-12-22 | |
| 2014-12-15 | Lobacki Joseph M Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +22,420 22,420 owned after | $104.08 exercise price | 2014-12-15 | |
| 2014-10-22 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 110,000 owned after | $10.59 exercise price | 2014-10-23 | |
| 2014-10-16 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 115,000 owned after | $10.59 exercise price | 2014-10-17 | |
| 2014-10-15 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 120,000 owned after | $10.59 exercise price | 2014-10-17 | |
| 2014-10-15 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,346 10,654 owned after | $9.39 exercise price | 2014-10-17 | |
| 2014-10-15 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 15,000 owned after | $6.74 exercise price | 2014-10-17 | |
| 2014-10-15 | Svoronos Dawn Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,523 5,523 owned after | $89.63 exercise price | 2014-10-16 | |
| 2014-09-18 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −25,000 125,000 owned after | $10.59 exercise price | 2014-09-18 | |
| 2014-09-17 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 150,000 owned after | $10.59 exercise price | 2014-09-18 | |
| 2014-09-17 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 15,000 owned after | $9.39 exercise price | 2014-09-18 | |
| 2014-09-17 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −15,000 30,000 owned after | $6.74 exercise price | 2014-09-18 | |
| 2014-09-09 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 160,000 owned after | $10.59 exercise price | 2014-09-11 | |
| 2014-08-27 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,300 180,000 owned after | $10.59 exercise price | 2014-08-28 | |
| 2014-08-26 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,700 194,300 owned after | $10.59 exercise price | 2014-08-28 | |
| 2014-08-13 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,500 20,000 owned after | $9.39 exercise price | 2014-08-14 | |
| 2014-08-13 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 45,000 owned after | $6.74 exercise price | 2014-08-14 | |
| 2014-08-12 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,500 32,500 owned after | $9.39 exercise price | 2014-08-12 | |
| 2014-08-08 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,000 45,000 owned after | $9.39 exercise price | 2014-08-12 | |
| 2014-07-22 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 52,500 owned after | $6.74 exercise price | 2014-07-23 | |
| 2014-07-02 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −12,000 58,000 owned after | $9.39 exercise price | 2014-07-07 | |
| 2014-06-27 | Adams Daniel Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,792 4,792 owned after | $77.77 exercise price | 2014-07-01 | |
| 2014-06-27 | BLICKENSTAFF KIM D Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,792 4,792 owned after | $77.77 exercise price | 2014-07-01 | |
| 2014-06-27 | FALBERG KATHRYN E Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,792 4,792 owned after | $77.77 exercise price | 2014-07-01 | |
| 2014-06-27 | Svoronos Dawn Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,792 4,792 owned after | $77.77 exercise price | 2014-07-01 | |
| 2014-06-27 | YARNO WENDY L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,792 4,792 owned after | $77.77 exercise price | 2014-07-01 | |
| 2014-06-27 | VERNON W ANTHONY Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,792 4,792 owned after | $77.77 exercise price | 2014-07-01 | |
| 2014-06-27 | Machado Clarence Patrick Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +4,792 4,792 owned after | $77.77 exercise price | 2014-07-01 | |
| 2014-06-18 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 60,000 owned after | $6.74 exercise price | 2014-06-19 | |
| 2014-06-03 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 67,500 owned after | $6.74 exercise price | 2014-06-19 | |
| 2014-04-15 | Bierly Rick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +31,023 31,023 owned after | $58.10 exercise price | 2014-04-18 | |
| 2014-02-18 | Hung David Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +133,000 133,000 owned after | $83.55 exercise price | 2014-02-20 | |
| 2014-02-18 | Rhodes Jennifer J Officer (GC & Chief Compliance Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,000 23,000 owned after | $83.55 exercise price | 2014-02-20 | |
| 2014-02-18 | Kelsey Stephen Michael Officer (SVP of New Projects) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $83.55 exercise price | 2014-02-20 | |
| 2014-02-18 | Cohen Cheryl Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,000 39,000 owned after | $83.55 exercise price | 2014-02-20 | |
| 2014-02-18 | Seely Lynn Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,000 39,000 owned after | $83.55 exercise price | 2014-02-20 | |
| 2014-02-18 | Machado Clarence Patrick Officer (Chief Business Officer and CFO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 7,294 owned after | $10.59 exercise price | 2014-02-19 | |
| 2014-02-11 | Machado Clarence Patrick Officer (Chief Business Officer and CFO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 47,294 owned after | $10.59 exercise price | 2014-02-12 | |
| 2014-02-05 | Machado Clarence Patrick Officer (Chief Business Officer and CFO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 87,294 owned after | $10.59 exercise price | 2014-02-06 | |
| 2014-01-28 | Machado Clarence Patrick Officer (Chief Business Officer and CFO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 127,294 owned after | $10.59 exercise price | 2014-01-29 | |
| 2014-01-27 | Hung David Director, Officer (President and CEO) | 4/A | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −150,000 50,000 owned after | $5.88 exercise price | 2014-02-04 | |
| 2014-01-27 | Hung David Director, Officer (President and CEO) | 4 | Employee Stock Option (right to buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −300,000 50,000 owned after | $5.88 exercise price | 2014-01-28 | |
| 2014-01-21 | Machado Clarence Patrick Officer (Chief Business Officer and CFO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −40,000 167,294 owned after | $10.59 exercise price | 2014-01-23 | |
| 2014-01-21 | Rhodes Jennifer J Officer (GC & Chief Compliance Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,000 42,000 owned after | $47.48 exercise price | 2014-01-23 |